Form 8-K Chemours Co For: Nov 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Chemours (CC) Tops Q3 EPS by 28c; adj.-EBITDA Rose ~59%
November 7, 2016 7:51 AM ESTChemours (NYSE: CC) reported Q3 EPS of $0.61, $0.28 better than the analyst estimate of $0.33. Revenue for the quarter came in at $1.4 billion versus the consensus estimate of $1.4 billion.
Highlights:
Continued progress on all transformation plan objectives, including cost reductions, growth initiatives and portfolio rationalizationImproved cash from operating activities by ~$440 million year-to-dateRetired $315 million of long term debt through October 31, 2016Generated ~$685 million in gross proceeds from Chemical Solutions divestituresIncreased full-year Adjusted EBITDA... More